Product	Indicant	Target PoC	Discovery	Pre-clinical	Phase1	Phase2	Phase3	NDA	Approval
Opiranserin(VVZ-149) for injection Unafra®	Postoperative pain
Opiranserin(VVZ-149) for external use	Acute pain
VVZ-2471 (taken orally)	Chronic pain/substance addiction/anxiety/depression
VVZ-3416 (taken orally)	Neurodegenerative diseases such as Parkinson’s disease
VVZ-N2-1 (taken orally)	Chronic pain/substance addiction
VVZ-N3 (taken orally)	Schizophrenia
VVZ-N4 (taken orally)	Treatment-resistant depression
VVZ-N5 (taken orally)	Thrombosis

Product/Indicant	Indicant	Status
Opiranserin(VVZ-149) for injection Unafra®	Postoperative pain	Phase 3 Progress
Opiranserin(VVZ-149) for external use	Acute pain	Phase 2 Progress
VVZ-2471 (taken orally)	Chronic pain/substance addiction/anxiety/depression	Phase1 Progress
VVZ-N2-1 (taken orally)	Chronic pain/substance addiction	Pre-clinical Progress
VVZ-E2 (taken orally)	Neurodegenerative diseases such as Parkinson’s disease	Discovery Progress
VVZ-N3 (taken orally)	Schizophrenia	Discovery Progress
VVZ-N4 (taken orally)	Treatment-resistant depression	Target PoC Progress
VVZ-N5 (taken orally)	Thrombosis	Target PoC Progress

Vivozon steadily has been developing VVZ-2471 as a second-generation analgesic drug candidate following Opiranserin, and has been diversifying various pipelines to develop innovative CNS drugs. Having setting up multi-target combinations through N2-1, N3, N4, and E2, Vivozon aims to cure chronic pain, substance use disorders, schizophrenia, depression as well as neurodegenerative diseases etc. In addition, Vivozon has developed the N5 project, which aims to cure thrombosis, a non-CNS-related disease. Vivozon eventually will become a biopharmaceutical company specialized in new drug discovery and development.